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Available online 7 January 2017Objectives. To compare the performance characteristics of 3 risk-stratiﬁcation models, referred to as Mayo,
Helsinki and Milwaukee models, in predicting lymphatic dissemination in endometrial cancer.
Methods. A total of 1052 patients with stage I–III endometrioid endometrial cancer were included in the
study. The areas under curve were compared with the receiver operating characteristic curve area comparison
test. Chi-square and Fisher exact test were used for comparing categorical variables. The Kaplan-Meier method
and multivariable Cox regression models were used for survival analyses. The median follow-up time was
55 months (range 1–108).
Results. Areas under curve were 0.781, 0.830 and 0.829 for the Mayo, Helsinki (P = 0.285 vs. Mayo) and
Milwaukee (P = 0.292 vs. Mayo) models, respectively, in predicting lymphatic dissemination. The rates of
false negatives and false positives were similar for all models. The lymphadenectomy rate decreased in the
order of Mayomodel (71.5%) N Helsinki model (62.4%) NMilwaukee model (48.8%). In patients with stage I can-
cer, disease speciﬁc survival was better for thosewho satisﬁed low-risk criteria according to any of themodels. In
patients with stage II–III cancer, this difference in survival was signiﬁcant only for the Milwaukee model. Both
lymphatic dissemination and high-risk tumor features as per the risk models were independent predictors of
survival.
Conclusions. The studiedmodels had a similar accuracy in predicting lymphatic dissemination in endometrial
cancer. Lymphadenectomy rate was lowest for the Milwaukee model. Survival analyses suggest that variables
included in the models predict patient outcome independently of tumor stage.
© 2017 Elsevier Inc. All rights reserved.Keywords:
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Risk-stratiﬁcation1. Introduction
The surgical treatment of patients with apparent early low-risk
endometrial cancer consists of total hysterectomy with bilateral
salpingo-oophorectomy. Pelvic-aortic lymphadenectomy is undertaken
in high-risk patients for accurate staging, which improves prognostica-
tion and allows triage for tailored adjuvant treatment [1].and Gynecology, University of
029 HUS, Helsinki, Finland.The recognition of true low-risk endometrial cancers remains a
challenge. In clinical practice, risk-stratiﬁcation is mainly based on pre-
operative or intraoperative identiﬁcation of the features of the primary
tumor (“uterine risk factors”), sometimes combined with tumor
markers in serum. A proper risk-stratiﬁcation method is accurate, and
concurrently associatedwith an acceptable lymphadenectomy rate. Ide-
ally, it should also facilitate the prediction of patient survival.
In 2000, Mariani et al. introduced a risk-stratiﬁcation schema that is
now vastly utilized to deﬁne low-risk endometrial cancers [2]. Accord-
ing to these Mayo criteria, named after the Mayo Clinic, Rochester,
MN, the low-risk group is comprised of tumors with grade 1–2
Table 1
Clinicopathologic data (n= 1052).
Age (years) (mean ± SD) 67.2 ± 10.4
Body mass index (kg/m2) (mean ± SD)a 28.7 ± 6.3
Pelvic lymphadenectomy (number of cases, percent) 550 (52.3%)
Pelvic-aortic lymphadenectomy (number of cases, percent) 134 (12.7%)
Lymph node yield, pelvic lymphadenectomy (mean ± SD)b 15.3 ± 8.0
Lymph node yield, pelvic-aortic lymphadenectomy (mean ± SD)c 26.1 ± 9.9
Laparoscopic hysterectomies (number of cases, percent)d 859 (81.7%)
Adjuvant therapy (number of cases, percent)
Vaginal brachytherapy 497 (47.2%)
Whole pelvic radiotherapy 144 (13.7%)
Chemotherapy 20 (1.9%)
Chemotherapy and vaginal brachytherapy 27 (2.6%)
Chemotherapy and whole pelvic radiotherapy 107 (10.2%)
Grade (number of cases, percent)
Grade 1 642 (61.0%)
Grade 2 264 (25.1%)
Grade 3e 146 (13.9%)
FIGO 2009 stage (number of cases, percent)
IA 653 (62.1%)
IB 216 (20.5%)
II 60 (5.7%)
IIIA 43 (4.1%)
IIIB 7 (0.7%)
IIIC1 51 (4.8%)
IIIC2 22 (2.1%)
a Number of cases 1051 (body mass index missing for 1 patient).
b Number of cases 542 (lymph node yield missing for 8 patients).
c Number of cases 132 (lymph node yield missing for 2 patient).
d Traditional laparoscopic hysterectomies, n= 789; robotic hysterectomies, n= 70.
e Including 16 carcinosarcomas.
Table 2
Risk-stratiﬁcation schemas.
Mayo Low risk
TD b2 cm, grade 1 or 2, MI b50%
MI 0%, any TD or grade
Low-intermediate risk
TD ≥2 cm or unknown, grade 1 or 2, MI b50%
High-intermediate risk
Grade 1 or 2, 50% bMI ≤ 66%
Grade 3, MI b50%
High risk
Grade 1 or 2, MI N66%
Grade 3, MI ≥50%
Adnexal metastasis
Helsinki Low risk
0 risk score pointsa
Low-intermediate to high risk
1–8 risk score points
Milwaukee Low risk
TD ≤50 mm, any grade, MI ≤33%
Low-intermediate risk
TD N50 mm, any grade, MI ≤33%
TD ≤50 mm, any grade, 33% bMI ≤ 66%
TD ≤50 mm, grade 1, MI N66%
High-intermediate risk
TD N50 mm, grade 1, 33% bMI ≤ 66%
TD ≤50 mm, grade 2 or 3, MI N66%
High risk
TD N50 mm, any grade, MI N66%
TD N50 mm, grade 2 or 3, 33% bMI ≤ 66%
MI, myometrial invasion; TD, tumor diameter.
a 1 point for thrombocytosis, 2 points for poor differentiation (grade 3), 2 points for TD
≥3 cm, 3 points for CA125 N35 U/mL.
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≤2 cm. Subsequently, Bogani et al. developed a 5-category risk-stratiﬁ-
cation system based on frozen section analysis where also noninvasive
endometrioid carcinomas are included as low-risk cases, regardless of
grade and size [3]. Recently, Cox Bauer et al. at the Aurora Sinai Medical
Center and St. Luke's Medical Center, Milwaukee, WI, introduced a
schema for endometrioid carcinomas that contains depth ofmyometrial
invasion and tumor size as parameters for identifying patients at low
risk for lymph node involvement, with low-risk criteria being satisﬁed
when the depth of invasion is ≤33% and diameter ≤50 mm, regardless
of grade [4]. This schema was based on ﬁndings on ﬁnal pathology but
the variables were considered potential intraoperative predictors of
lymphatic dissemination. Notably, the authors reported that these
novel low-risk criteria allow for an additional 20% of patients to be
spared surgical lymph node assessment, compared with the Mayo
criteria.We have earlier demonstrated a combined preoperative and in-
traoperative scoring system for a prediction of stage IIIC–IV endometrial
cancer [5]. Patients at low risk for an advanced disease were those with
a normal platelet count and CA125 value, and grade 1–2 endometrioid
carcinoma of b3 cm in size according to preoperative histology and
gross visual inspection.
To test the universal applicability of the risk models by Bogani et al.
[3] and Cox Bauer et al. [4], we validated the ﬁndings of the original
studies in our own cohort of endometrial cancer patients. The perfor-
mance characteristics of the 2 models were compared with our own
published model [5]. Further, we assessed the value of each model as
a prognostic tool in endometrial cancer.
2. Materials and methods
Patients who underwent primary surgical treatment for stage I-IIIC
endometrioid endometrial cancer at the Department of Obstetrics and
Gynecology, Helsinki University Hospital, between January 1, 2007
and December 31, 2013 were included in this study (n = 1052).
Carcinosarcomas (n= 16) were included as high grade endometrioid
carcinomas [6]. Indications for lymphadenectomy in our cohort have
been reported earlier [7]. Brieﬂy, the initial strategy was to perform
pelvic lymphadenectomy routinely in all patients, and para-aortic
lymphadenectomy selectively in patients considered to be at highest
risk for lymph node metastasis. As of January 2012, routine pelvic
lymphadenectomy was abandoned and the decision on lymphadenec-
tomy was based on preoperative histology and assessment of local dis-
ease spread by magnetic resonance imaging. Pertinent patient
characteristics and surgical and pathology data are shown in Table 1.
Stage was determined according to the International Federation of
Gynecology and Obstetrics (FIGO) guidelines revised in 2009 [8].
We compared 3 risk-stratiﬁcation models for endometrioid endo-
metrial cancer, referred to in the following as Mayo [3], Helsinki [5]
and Milwaukee [4] models. For each model, the area under the receiver
operating characteristic curve was built. Unlike the previously reported
Mayo criteria [3,9], frozen section analysis was not available to us for re-
view. Thus, womenwere identiﬁed as being at low risk for nodalmetas-
tasis based on modiﬁed Mayo criteria: grade 1–2 endometrioid
histology, myometrial invasion b50% and diameter b2 cm on ﬁnal pa-
thology reports [10], and noninvasive cancers of any grade and size
[3]. Findings on ﬁnal pathology were also used for validation of the
Helsinki and Milwaukee models. Similar to the Cox Bauer study [4],
we restricted our analysis to stage I–IIIC cancers of the endometrioid
type, although the original Helsinki model also considered stage IV
and nonendometrioid carcinomas [5]. Risk schemas for the different
models are detailed in Table 2. Patients with available data for all risk
parameters considered in each model were included in the calculations
(n=1045 for theMayomodel, n=881 for theHelsinkimodel, n=987
for the Milwaukee model).
For the Helsinki model, pretreatment serum CA125 concentration
was quantitated with the chemiluminescent microparticleimmunoassay on the Abbott Architect 2000i Analyzer (Abbott Diagnos-
tics, Abbott Park, IL). The concentration was considered increasedwhen
N35 U/mL [11]. Last pretreatment platelet count was analyzed by elec-
trical impedance technology and ﬂow cytometry. Thrombocytosis was
deﬁned as a platelet count N360 × 109/L [12].
The areas under curve were comparedwith the 2-tailed receiver op-
erating characteristic curve area comparison test. Chi-square and Fisher
Table 3
Areas under curve (AUC) for 3 models in predicting lymphatic dissemination in endometrioid endometrial cancer.
AUC (95% CI) P vs. Mayo (2-tailed) P vs. Helsinki (2-tailed)
All patients
Mayo (n= 1045) 0.781 (0.729–0.832)
Helsinki (n= 881) 0.830 (0.790–0.871) 0.285
Milwaukee (n= 987) 0.829 (0.777–0.882) 0.292 0.982
Patients who underwent lymphadenectomy
Mayo (n= 678)a 0.761 (0.703–0.818)
Helsinki (n= 583)b 0.815 (0.767–0.863) 0.280
Milwaukee (n= 631)c 0.806 (0.746–0.865) 0.368 0.855
a Pelvic lymphadenectomy, n= 546; pelvic-aortic lymphadenectomy, n= 132.
b Pelvic lymphadenectomy, n= 463; pelvic-aortic lymphadenectomy, n= 120.
c Pelvic lymphadenectomy, n= 504; pelvic-aortic lymphadenectomy, n= 127.
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ic survival, deﬁned as the time from date of surgery to death from endo-
metrial cancer, was estimated using the Kaplan-Meier method.
Differences between groups were compared using the log rank test.
The joint effect of 2 factors on survival was assessed usingmultivariable
Cox regression analysis. The median follow-up time was 55 months
(range 1–108). Statistical signiﬁcance was set at P b 0.05. Data were
analyzed using IBM SPSS version 22 software (IBM Corp., Armonk, NY).
3. Results
Areas under curve were 0.781, 0.830 and 0.829 for the Mayo,
Helsinki and Milwaukee models, respectively, in predicting lymphatic
dissemination in endometrioid endometrial cancer, indicating a fair to
good discrimination power for all models (Table 3). Differences in
areas under curve were not signiﬁcant (Table 3). These ﬁndings
retained after exclusion of patients who did not undergo pelvic or
pelvic-aortic lymphadenectomy (Table 3).
Diagnostic indices in predicting lymphatic dissemination by the 3
models are shown in Table 4. With cut-off set at low-intermediate risk
for the Mayo and Milwaukee models and 1 risk score point for the
Helsinki model, sensitivity was highest for the Helsinki model and
speciﬁcity highest for the Milwaukee model. These ﬁndings remained
unaltered when the analyses were restricted to patients who
underwent pelvic or pelvic-aortic lymphadenectomy (Table 4). Despite
the observed differences in sensitivities and speciﬁcities, the rates of
false negatives and false positives were similar for all models (Table 5).
Lymphadenectomy rates corresponded to the proportion of patients
who did not satisfy low-risk criteria according to the Mayo and
Milwaukee criteria, or had ≥1 risk score points according to the Helsinki
criteria. The expected lymphadenectomy ratewas 71.5% (747/1045) for
the Mayo model, 62.4% (550/881) for the Helsinki model (odds ratio
0.66 [95% conﬁdence interval 0.55–0.80] vs. Mayo; P b 0.0001), and
48.8% (482/987) for the Milwaukee model (odds ratio 0.57 [95%
conﬁdence interval 0.48–0.69] vs. Helsinki; P b 0.0001).
In patients with stage I cancer, disease speciﬁc survival was better
for those who satisﬁed low-risk criteria according to any of the models
(Fig. 1A–C). This result also pertained to a subgroup of patients whoTable 4
Diagnostic indices for 3 models in predicting lymphatic dissemination in endometrioid endom
models and 1 risk score point for the Helsinki model.
Sensitivity
(95% CI)
Speciﬁcity
(95% CI)
All patients
Mayo (n= 1045) 94.4% (86.2%–98.4%) 30.2% (27.3%–
Helsinki (n= 881) 100% (94.5%–100%) 40.6% (37.2%–
Milwaukee (n= 987) 91.0% (81.5%–96.6%) 54.2% (51.0%–
Patients who underwent lymphadenectomy
Mayo (n= 678) 93.8% (84.8%–98.3%) 28.0% (24.5%–
Helsinki (n= 583) 100% (93.8%–100%) 37.1% (33.0%–
Milwaukee (n= 631) 90.0% (79.5%–96.2%) 50.6% (46.4%–underwent surgical staging (Supplemental Fig. S1). In patients with
stage II-III cancer, the difference in survival was signiﬁcant only for the
Milwaukee model (P=0.034) (Fig. 1D–F). In Cox multivariable disease
speciﬁc survival analyses, both lymphatic dissemination (stage IIIC) and
high-risk tumor features as per the risk models were recognized as
independent predictors of survival (Table 6).
4. Discussion
The surgical treatment of patients with endometrial cancer is nowa-
days tailored based on individual risk-assessment. Those at low risk for
extrauterine disease do not beneﬁt from lymphadenectomy and are
generally treatedwith hysterectomyand bilateral salpingo-oophorecto-
my alone. This practice decreases the risk for intraoperative complica-
tions, such as vessel and nerve damage, and protects patients from the
development of long-term sequelae of lymphadenectomy, including
lower-extremity lymphedema and pelvic lymphatic cysts.
Numerous algorithms have been developed for the recognition of
endometrial cancer patients who are at low risk for lymphatic spread.
While the performance characteristics of the Mayo model have been
veriﬁed prospectively [10] and in a population-based analysis [13],
those of the other algorithms are usually based on single-institution
experience. Here, we wanted to compare a modiﬁed Mayo model with
Helsinki and Milwaukee models, both of which were recently intro-
duced for the improvement of risk-assessment of endometrial cancer
patients. The potential beneﬁt of the Helsinki model lies in its clinical
applicability, as its use does not require frozen section analysis or imag-
ing studies [5]. The Milwaukee model, on the other hand, was reported
to markedly reduce the number of lymphadenectomies performed on
low-risk patients [4].
In a population-based analysis of patients with stage I or IIIC
endometrioid endometrial cancer, 21.1% of the patients satisﬁed low-
risk Mayo criteria, deﬁned as grade 1–2 endometrioid histology,
myometrial invasion b50%, and tumor diameter ≤2 cm [13]. The higher
proportion (28.5%) of low-risk patients in our study is partly explained
by the fact that we adhered to Mayo criteria that include noninvasive
cancers of any grade and size as low-risk cancers [3]. Further, stage II-
IIIB cancers were included in our calculations. Without consideringetrial cancer. The cut-off was set at low-intermediate risk for the Mayo and Milwaukee
Positive predictive value (95% CI) Negative predictive value (95% CI)
33.2%) 9.0% (7.0%–11.3%) 98.7% (96.6%–99.6%)
44.0%) 11.8% (9.2%–14.8%) 100% (98.9%–100%)
57.5%) 12.7% (9.8%–16.0%) 98.8% (97.4%–99.6%)
31.8%) 12.0% (9.3%–15.1%) 97.7% (94.3%–99.4%)
41.4%) 15.0% (11.6%–18.9%) 100% (98.1%–100%)
54.8%) 16.1% (12.3%–20.4%) 98.0% (95.6%–99.3%)
Table 5
False negative and false positive rates for 3 models in predicting lymphatic dissemination in patients with endometrioid endometrial cancer who underwent lymphadenectomy. The cut-
off was set at low-intermediate risk for the Mayo and Milwaukee models and 1 risk score point for the Helsinki model.
False negative rate P vs. Mayo
OR (95% CI)
P vs. Helsinki
OR (95% CI)
False positive rate P vs. Mayo
OR (95% CI)
P vs. Helsinki
OR (95% CI)
Mayo 4/176 (2.3%) 442/502 (88.0%)
Helsinki 0/195 (0%) 0.050 330/388 (85.1%) 0.191
0.98 (0.96–1.0) 0.77 (0.52–1.1)
Milwaukee 6/295 (2.0%) 1.0 0.086 282/336 (83.9%) 0.088 0.677
0.89 (0.25–3.2) 1.0 (1.0–1.0) 0.71 (0.48–1.1) 0.92 (0.61–1.4)
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exclusion of stage II-IIIB cancers, the proportion of low-risk patients
was 25.8% (242/937) in our sample, which is more comparable to that
reported earlier [13]. The risk for lymph node metastasis in surgically
staged low-risk Mayo patients was reported as 1.4% [13], which is in
the same range as in our low-risk patients who underwent lymphade-
nectomy (2.3%).
In the study by Cox Bauer et al. [4], 38.8% of the patients had a low-
risk cancer according to the Milwaukee rules (51.2% in our study), and
their risk for lymph node involvement was 0% (2.0% in our study). The
higher proportion of low-risk patients in our study did not diminish
the accuracy of the model, as its area under curve in predicting lymph
node metastasis was 0.829, i.e. fairly similar to that in the discovery co-
hort (0.837) [4]. As expected, the ﬁndings concerning the Helsinki
model were similar to those in our earlier report [5], although the
inclusion criteria were slightly different from the original and tumor
grade was based on ﬁndings in the hysterectomy specimens instead of
preoperative endometrial samples.
All of the tested models had similar areas under curve in predicting
lymphatic dissemination in endometrioid endometrial cancer. More-
over, the rates of false negatives and false positives were similar for all
models. The Milwaukee model was associated with the lowest lymph-
adenectomy rate, a beneﬁcial feature when avoidance of unnecessary
lymphadenectomies is considered a quality measure. However, as
both the Cox Bauer study [4] and the current analysis were based on
ﬁndings on ﬁnal pathology, institutions that consider implementation
of the Milwaukee schema in clinical practice will need to validate itFig. 1. Kaplan-Meier estimations for disease speciﬁc survival in patients with stage I (A, B,
stratiﬁcation models.with techniques that will be used for the assessment of the depth of
myometrial invasion and tumor size. Frozen section analysis has been
shown to be reliable in assessing the features of the primary tumor, al-
though a large sample ﬂow may be a prerequisite for the development
of an appropriate pathology expertise in a frozen section practice [14,
15]. The reliability of imaging techniques may generally not be high
enough in assessing the local spread of endometrial cancer; in a multi-
center prospective study, the sensitivities of transvaginal ultrasound
and magnetic resonance imaging in detecting deep (≥50%) myometrial
invasion were 71% and 87%, respectively [16]. Tumor diameter can be
easily measured on fresh tissue intraoperatively and is unchanged on
ﬁnal pathology [17].
Koskas et al. performed an external validation of the Helsinki model
and found that it had a low discrimination power in predicting stage
IIIC-IV disease in their sample of 374 women (area under curve 0.68)
[18]. It should be noted that the sample was somewhat anomalous re-
garding the proportion of type 2 and advanced cancers, as 22.7% were
serous or clear cell carcinomas and 17.4% were stage IIIC-IV cancers. In
our original study [5], the proportion of serous and clear cell carcinomas
was 8.2% which corresponds to the common estimate of 10% as their
proportion [19]. The proportion of stage IIIC-IV cancers was 11.1% in
our study [5] which is fairly similar to the proportion of 7.9% in the
Surveillance, Epidemiology, and End Results database [20]. These differ-
ences may explain why all risk parameters in the discovery cohort [5]
were not signiﬁcant predictors of an advanced disease in the validation
cohort [18]. The accuracy of the scoring system might have been better
if the aberrations in the validation cohort had been taken into accountC) or stage II–III (D, E, F) endometrioid endometrial cancer according to different risk-
Table 6
Cox multivariable disease speciﬁc survival analyses in patients with endometrioid endo-
metrial cancer.
HR (95% CI) P
Stage
I–IIIB (n= 974) 1
IIIC (n= 71) 4.9 (3.1–7.8) b0.0001
Mayo model
Low risk (n= 298) 1
Low-intermediate to high risk (n= 747) 4.7 (2.2–10) b0.0001
Stage
I–IIIB (n= 816) 1
IIIC (n= 65) 5.0 (3.1–7.9) b0.0001
Helsinki model
0 risk score points (n= 331) 1
1–8 risk score points (n= 550) 3.0 (1.6–5.5) b0.0001
Stage
I–IIIB (n= 920) 1
IIIC (n= 67) 4.8 (3.0–7.7) b0.0001
Milwaukee model
Low risk (n= 505) 1
Low-intermediate to high risk (n= 482) 2.9 (1.7–4.8) b0.0001
514 T. Tuomi et al. / Gynecologic Oncology 144 (2017) 510–514by calculating the risk score points as described [5], instead of using
original points as such.
Patients with stage I cancer not satisfying low-risk criteria according
to any of the models had a poorer disease speciﬁc survival than those
with stage I low-risk cancer, which can be explained by the notion
that uterine risk factors predict the outcome of endometrial cancer pa-
tients independently of nodal status [21,22]. This emphasizes the need
for a 2-step risk-stratiﬁcation in endometrial cancer. In the ﬁrst phase,
the risk for lymphatic dissemination is assessed preoperatively and/or
intraoperatively, and this information is used to determine the need
for lymphadenectomy. In the second phase, the need for adjuvant ther-
apy is primarily determined by ﬁnal histology and stage. However, be-
cause some patients with a local endometrioid cancer will have a
poorer than expected outcome based on stage alone, additional vari-
ables will need to be considered in their risk-assessment. Currently,
these mainly include uterine risk factors and patient age, but molecular
classiﬁcation of the tumors will probably allow reﬁnement of adjuvant
therapy decisions in the future [23]. The need for an accurate and com-
prehensive risk-assessment is emphasized by the fact that the propor-
tion of patients with stage I cancer and poor outcome may be even
higher than that of patients with stage IIIC cancer. Of the patients with
stage I cancer in our study population, 10.0% (87/869) had a disease
relapse during follow-up, a higher proportion than the proportion of
patients who had primary lymph node metastasis (6.9%) (Table 1).
In summary, the studiedmodels had similar accuracies in predicting
lymphatic dissemination in endometrioid endometrial cancer. Our ﬁnd-
ings regarding theMayo model and the Milwaukee model are in agree-
ment with earlier studies [4,13], which demonstrates external validity.
The low lymphadenectomy rate associated with the Milwaukee model
may encourage its validation as a preoperative or intraoperative risk-
stratiﬁcation schema by incorporating imaging or frozen section in the
assessment of the depth of myometrial invasion. Patients with a non-
low-risk local endometrial cancer cannot be assured of a similarly
good outcome as patients with a low-risk local disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygyno.2017.01.003.
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